Global Nuclear Medicine Market - Growth, Trends & Forecasts 2017 - 2022

  • ID: 4387355
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 4
The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2021. Nuclear medicine utilizes the radioisotope for application in diagnosis and treatment of diseases. The drugs containing radionuclides are called radiopharmaceuticals. The uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

The use of nuclear medicines for diagnostic purposes has gained huge popularity all around the world. There has been increased use of SPECT, PET, CT, and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimerdisease, coronary heart diseases, bone metastasis, cancers and different medical conditions affecting the thyroid gland, and scar tissue removal. Advancement in diagnostic imaging is bringing in more use of nuclear medicine. Nuclear cardiology has gained great popularity in North America.

Global Nuclear Medicines Market- Market Dynamics

The report lists several driving and restraining factors for the global nuclear medicines market. In addition, it sheds light on several opportunities that exist for the market players. Some of these are listed below.

Drivers

Increasing incidence and prevalence of cancer and cardiac ailments

Increasing application of SPECT and PET with advancement of technology

Growing awareness amongst physicians

Public awareness for better healthcare

Restraints

Short half-life of radiopharmaceuticals

High capital investment required for development

Stringent regulatory guidelines

Opportunities

Increasing imaging technologies

Potential radioisotopes in pipeline

Increasing neurological applications and cyclotron based production

The global nuclear medicine market has been segmented based on type, application, and geography.

Based on the type of product, the market has been segmented into the diagnostic market and therapeutic market, wherein the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes (subdivided intoRubidium-82, Flourine-18). The therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters (includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192).

The segmentation based on the application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in cardiology, neurology, oncology and others. The therapeutic applications include application in oncology, thyroid, endocrinology and various other therapeutic areas.

The global nuclear medicine market has been geographically segmented into North America (includes United States, Canada, and Mexico), Europe (includes Germany, UK, France, Italy Spain, Russia and Others), Asia-Pacific (includes China, Japan, India, Australia South Korea and Others), Middle East and Africa (includes UAE, Saudi Arabia, Israel, and others), and Latin America (includes Brazil, Argentina, Mexico, and others). Due to high technological advancement coupled with a developed economy, North America has the largest market share, followed by Europe and Asia-Pacific.

Currently, the segment of diagnostics holds the largest share in nuclear medicines market, where SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.

This Report Offers:

Market definition for the nuclear medicines market along with identification of key drivers and restraints for the market.

Market analysis for the nuclear medicines market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the nuclear medicines market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 MARKETS COVERED
1.3 MAJOR STAKEHOLDERS
1.4 RESEARCH METHODOLOGY
2 EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Market Drivers
3.1.1 Increasing Incidents of Cancer and Cardiac Ailments
3.1.2 Increasing SPECT AND PET applications
3.1.3 Growing Public Awareness for healthcare
3.2 MARKET CONSTRAINTS
3.2.1 Short Half-life of Radiopharmaceuticals
3.2.2 High Capital Investment
3.2.3 Regulatory Guidelines
3.2.4 Reimbursement
3.3 OPPORTUNITIES
3.3.1 Increasing Imaging Technologies
3.3.2 Potential Radioisotopes in Pipeline
3.3.3 Increasing Neurological Applications
3.3.4 Cyclotron based production
3.4 THREATS
3.4.1 Shutdown of Nuclear Reactors
4. GLOBAL NUCLEAR MEDICINE MARKET SEGMENTATION
4.1 Introduction
4.2 Global Market: Segmentation by Diagnostics
4.2.1 Introduction
4.2.2 SPECT Market
4.2.3 PET Market
4.3 Global Market: Segmentation by Therapeutics
4.3.1 Introduction
4.3.2 Alpha Emitters
4.3.3 Beta Emitters
4.3.4 Brachytherapy
4.4 GLOBAL MARKET SEGMENTATION BY APPLICATION
4.4.1 SPECT Market
4.4.2 PET Market
4.5 MARKET SEGMENTATION BY GEOGRAPHY
4.5.1 North America Nuclear Medicine Market
4.5.1.1 UNITED STATES
4.5.1.2 CANADA
4.5.1.3 MEXICO
4.5.2 EUROPE
4.5.2.1 GERMANY
4.5.2.2 UNITED KINGDOM
4.5.2.3 FRANCE
4.5.2.4 SPAIN
4.5.2.5 ITALY
4.5.3 ASIA - PACIFIC
4.5.3.1 India
4.5.3.2 China
4.5.3.3 South Korea
4.5.3.4 Japan
5. COMPETITIVE LANDSCAPE
5.1 MERGERS, ACQUISITIONS & SPIN OFFS
5.2 COLLABORATIONS
5.3 PRODUCT LAUNCHES
6. PROFILES OF KEY COMPANIES
6.1 MALLINCKRODT
6.2 LANTHEUS MEDICAL IMGAGING
6.3 IBA GROUP
6.4 TRIAD ISOTOPE
6.5 SIEMENS HEALTHCARE
6.6 NTP RADIOISOTOPES
6.7 Bracco Imaging S.P.A.
6.8 BRACCO PHARMA
6.9 Cambridge Isotope Laboratories, Inc.
6.10 Cardinal Health, Inc.
6.11 GE Healthcare (Subsidiary of General Electric Company)
6.12 Nordion, Inc.
6.13 Taiyo Nippon Sanso Corporation
6.14 Fujifilm Holdings Corporation
6.15 Eczacibasi-Monrol
6.16 Isotec, Inc. (Sigma-Aldrich)
6.17 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
7. Appendix
7.1 Abbreviations
7.2 Sources
7.3 Bibliography
7.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll